The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

In this video, Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with ...

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.